Innate Pharma (IPHA) Long-Term Debt Repayments (2019 - 2025)
Innate Pharma's (IPHA) quarterly Long-Term Debt Repayments came in at -$10.4 million in Q4 2025, down 8.63% YoY from -$11.4 million in Q4 2024, and down 8.63% on a QoQ basis from -$9.5 million in Q4 2024.
Innate Pharma (IPHA) Long-Term Debt Repayments (2019 - 2025) Analysis & Trends
Innate Pharma (IPHA) has 7 years of Long-Term Debt Repayments data on file, last reported at -$10.4 million in Q4 2025.
- Quarterly Long-Term Debt Repayments fell 8.63% year-over-year to -$10.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$27.2 million (down 46.47% YoY) and the FY2025 annual result came in at -$10.4 million, down 8.63% from the prior year.
- Long-Term Debt Repayments slipped to -$10.4 million in Q4 2025, from -$9.5 million in the prior quarter.
- In the past five years, Long-Term Debt Repayments ranged from a high of -$1.0 million in Q2 2022 to a low of -$10.4 million in Q4 2025.
- A 5-year average of -$4.0 million and a median of -$2.4 million in 2021 frame the typical range for Long-Term Debt Repayments.
- Annual changes were most pronounced in 2022 — Long-Term Debt Repayments advanced 24.68% — and 2024, when it plunged 275.9%.
- Tracing IPHA's Long-Term Debt Repayments over 5 years: stood at -$2.4 million in 2021, then grew by 12.67% to -$2.1 million in 2022, then fell by 22.9% to -$2.5 million in 2023, then tumbled by 275.9% to -$9.5 million in 2024, then dropped by 8.63% to -$10.4 million in 2025.
- The last three Long-Term Debt Repayments figures came in at -$10.4 million (Q4 2025), -$9.5 million (Q4 2024), and -$4.8 million (Q2 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Repayments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.60 Bn | 130.75 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.93 Bn | 77.93 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 65.06 Bn | 59.88 Bn | 1.37 Bn | - |
| 4 | Moderna | 56.22 Bn | 51.08 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 42.03 Bn | 36.93 Bn | 1.53 Bn | 17.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.65 Bn | 28.34 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 27.70 Bn | 9.31 Bn | 668.28 Mn | -10.01 Mn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.31 Bn | 26.48 Bn | - | - |
| 10 | Innate Pharma | 199.79 Mn | 199.79 Mn | - | -10.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -10.37 Mn |
| Dec 31, 2025 | -10.37 Mn |
| Dec 31, 2024 | -9.55 Mn |
| Dec 31, 2024 | -9.55 Mn |
| Jun 30, 2024 | -4.76 Mn |
| Jun 30, 2024 | -4.76 Mn |
| Dec 31, 2023 | -2.54 Mn |
| Dec 31, 2023 | -2.54 Mn |
| Jun 30, 2023 | -1.74 Mn |
| Jun 30, 2023 | -1.74 Mn |
| Dec 31, 2022 | -2.07 Mn |
| Dec 31, 2022 | -2.07 Mn |
| Jun 30, 2022 | -1.02 Mn |
| Jun 30, 2022 | -1.02 Mn |
| Dec 31, 2021 | -2.37 Mn |
| Dec 31, 2021 | -2.37 Mn |
| Jun 30, 2021 | -1.36 Mn |
| Jun 30, 2021 | -1.36 Mn |
| Dec 31, 2020 | -2.68 Mn |
| Dec 31, 2020 | -2.68 Mn |